ArgusEye, a Stockholm, Sweden-based company that develops cutting-edge sensor technologies for biological system monitoring in real time, has secured €2.8 million in investment.
Investors
- Voima Ventures
- Eir Ventures
Use of funds
The money will be used by the business to advance the Auga sensor system platform’s development and quicken the bioprocessing workflow.
About ArgusEye
ArgusEye, under the direction of Erik Martinsson and Daniel Aili, creates innovative sensors that allow for the real-time observation and examination of biological systems and activities. The company’s first product, the AugaOneTM, was unveiled in March 2024 and is designed exclusively for downstream processing to boost process efficiency and intensify process development to speed up the detection and quantification of mAbs.
“As ArgusEye enters its scale-up phase, our focus is twofold: expanding our market footprint geographically and diversifying our product offerings to encompass the entire pharmaceutical process chain, from upstream cell growth to downstream purification and late-stage formulation as well as GMP production. This strategic approach is in line with our goal of enabling a more sustainable and democratic reach for biomedicines and transforming biopharma manufacturing through real-time inline quality control. We are also committed to providing innovative solutions that meet the changing needs of the biopharmaceutical industry.”This is Erik Martinsson, CEO of ArgusEye, commenting on the news.
